Richard Aplenc [clinicaltrials_resource:62bdabfcaa1e20c7043e70ffff8d7aea]
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate [clinicaltrials:NCT00316953]Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT01371981]
overall official [clinicaltrials_vocabulary:overall-official]
Richard Aplenc [clinicaltrials_resource:62bdabfcaa1e20c7043e70ffff8d7aea]
Bio2RDF identifier
62bdabfcaa1e20c7043e70ffff8d7aea
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:62bdabfcaa1e20c7043e70ffff8d7aea
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
becomingapatient@coh.org
last name [clinicaltrials_vocabulary:last-name]
Richard Aplenc
phone [clinicaltrials_vocabulary:phone]
205-934-0309
phone ext [clinicaltrials_vocabulary:phone-ext]
role [clinicaltrials_vocabulary:role]
Principal Investigator
identifier
clinicaltrials_resource:62bdabfcaa1e20c7043e70ffff8d7aea
title
Richard Aplenc
@en
type
label
Richard Aplenc [clinicaltrials_resource:62bdabfcaa1e20c7043e70ffff8d7aea]
@en